Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University

International Journal of Urology

Volumn 13, Issue 6, 2006, Pages 834-837

  Hinata, Nobuyuki ^a,c   Shirakawa, Toshiro ^a,b   Terao, Shuji ^a   Goda, Kazumasa ^a   Tanaka, Kazushi ^a   Yamada, Yuji ^a   Hara, Isao ^a   Kamidono, Sadao ^a   Fujisawa, Masato ^a   Gotoh, Akinobu ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Department of Urology   (Japan)

Author keywords

Adenovirus; Gene therapy; Prostate cancer

Indexed keywords

ADENOVIRUS VECTOR; OSTEOCALCIN; THYMIDINE KINASE; VALACICLOVIR;

ADENOVIRUS; ADULT; ADVANCED CANCER; AGED; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEVER; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; JAPAN; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SIDE EFFECT; TUMOR RECURRENCE;

ACYCLOVIR; ADENOVIRIDAE; AGED; ANTIVIRAL AGENTS; BONE NEOPLASMS; GENE THERAPY; HOSPITALS, UNIVERSITY; HUMANS; JAPAN; MALE; MIDDLE AGED; OSTEOCALCIN; PROSTATIC NEOPLASMS; THYMIDINE KINASE; VALINE;

EID: 33745236865     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01418.x     Document Type: Article

References (10)

1. Matsubara S Wada Y Gardner TA et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 2001 61: 6012 19.
2. Ko SC Cheon J Kao C et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 1996 15: 4614 19.
3. Cheon J Ko SC Gardner TA et al. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther. 1997 4: 359 65.
4. Gardner TA Ko SC Kao C et al. Exploiting stromal-epithelial interaction for model development and new strategies of gene therapy for prostate cancer and osteosarcoma metastases. Gene Ther. Mol. Biol. 1998 2: 41 58.
5. Shirakawa T Ko SC Gardner TA et al. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Ther. 1998 5: 274 80.
6. Kubo H Gardner TA Wada Y et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther. February 10 2003 14: 227 41.
7. Ko SC Cheon J Kao C et al. Osteocalcin-promotor -based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 1996 56: 4614 19.
8. Miles BJ Shalev M Aguilar-Cordova E et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Ther. November 1 2001 12: 1955 67.
9. Mullen CA Anderson L Woods K Nishino M Petropoulos D. Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses. Hum. Gene Ther. September 20 1998 9: 2019 30.
10. Kramm CM Korholz D Rainov NG et al. Systemic activation of the immune system during ganciclovir treatment following intratumoral herpes simplex virus type 1 thymidine kinase gene transfer in an adolescent ependymoma patient. Neuropediatrics February 2002 33: 6 9.